One issue for me is that the OMER drug is earlier in the complement pathway than is Soliris - see my comment here: http://www.siliconinvestor.com/readmsg.aspx?msgid=29434460 An aHUS expert might well have an answer to this theoretical concern of mine based on the data released today. Peter